Condition: Non-Small Cell Lung Cancer · Head and Neck Squamous Cell Carcinoma · Micro Satellite Stable Colorectal Cancer · Sponsor: AbbVie
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which cancer cells form in the tissues of the head and neck. The purpose of this study is to assess adverse events and pharmacokinetics of azirkitug as a monotherapy and in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan. Bevacizumab is an approved product, while budigalimab, azirkitug, and telisotuzumab adizutecan are investigational drugs being developed for the treatment of NSCLC, HNSCC, and other solid tumors. Study doctors put the participants in groups called treatment arms. The maximum-tolerated dose (MTD)/maximum administered dose (MAD) of azirkitug will be explored. Each treatment arm receives a different dose of azirkitug in monotherapy and in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan. Approximately 694 adult participants will be enrolled in the study across approximately 80 sites worldwide. Participants will receive azirkitug as a monotherapy or in combination with budigalimab, bevacizumab, or telisotuzumab adizutecan as an Intravenous (IV) Infusion for an estimated treatment period of up to 2 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will atten…
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| City of Hope National Medical Center /ID# 276272 | Duarte, California, United States | Recruiting |
| City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278589 | Irvine, California, United States | Recruiting |
| USC Norris Comprehensive Cancer Center /ID# 279603 | Los Angeles, California, United States | Recruiting |
| University of Illinois Hospital and Health Sciences System /ID# 251750 | Chicago, Illinois, United States | Recruiting |
| University of Chicago Medical Center /ID# 276271 | Chicago, Illinois, United States | Recruiting |
| Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593 | Fort Wayne, Indiana, United States | Recruiting |
| Community Health Network, Inc. /ID# 243011 | Indianapolis, Indiana, United States | Recruiting |
| Norton Cancer Institute /ID# 248903 | Louisville, Kentucky, United States | Recruiting |
| START Midwest /ID# 248685 | Grand Rapids, Michigan, United States | Recruiting |
| M Health Fairview University of Minnesota Medical Center - East Bank /ID# 276200 | Minneapolis, Minnesota, United States | Recruiting |
| Nebraska Cancer Specialists - Omaha - Wright Street /ID# 247399 | Omaha, Nebraska, United States | Recruiting |
| Duke Cancer Institute /ID# 276267 | Durham, North Carolina, United States | Recruiting |
+ 36 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05005403